Here are six things to know:
1. Dr. Chang is the executive director of the University of California Irvine Health H.H. Chao Comprehensive Digestive Disease Center.
2. The EsophyX Z recently received FDA clearance.
3. Surgeons performtheTIF procedure, an incisionless procedure to treat gastroesophageal reflux disease’s symptoms, using the EsophyX device. The EsophyX Z is the device’s third generation.
4. Through the TIF procedure using the EsophyX Z device, physicians can reconstruct the gastroesophageal valve by performing a partial fundoplication.
5. Additionally, the the EsophyX Z device is compatible with the company’s existing 7.5 mm SerosaFuse Implantable Fastener cartridges.
6. The EsophyX Z device will enter a limited release in the United States before full commercialization during the summer of 2016.
More articles on GI/endoscopy:
Global capsule endoscopy market to grow at CAGR 14.8% until 2020: 5 trends
Expectant mothers taking IBD medication may impact their newborns — 5 points
SonarMD equipped with new features — 5 observations
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.